Latest Conference Articles

Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.

Zamtocabtagene autoleucel induced responses, including durable complete responses, in relapsed/refractory diffuse large B-cell lymphoma.

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor activity in patients with relapsed/refractory multiple myeloma.

High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

CTCm from circulating tumor cells correlated with outcomes in mCRPC patients treated with bavdegalutamide in the ARDENT trial.

Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU Cancers Symposium.

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

Darolutamide plus ADT improved outcomes in metastatic hormone-sensitive prostate cancer, regardless of disease volume, in the phase 3 ARANOTE trial.

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for intermediate-risk prostate cancer.

Darolutamide with ADT and docetaxel benefits both younger and older patients with metastatic hormone-sensitive prostate cancer, per post hoc analysis.

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic castration-resistant prostate cancer.

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate cancer, stressing need for improvement.

G-CSF plus docetaxel modification allowed almost all patients with mHSPC to receive an efficacious dose of docetaxel plus darolutamide/ADT.

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic castration-resistant prostate cancer.

NKTR-255 with CD19 chimeric antigen receptor T-cell therapy improved 6-month complete response rates in relapsed/refractory large B-cell lymphoma.

Anakinra failed to reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient patients seeing a 14-month gain and 38% lower death risk.

As the 2025 ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment for prostate, kidney, bladder, and other genitourinary cancers.

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.

Susumu Hijioka, MD, discusses the key takeaways from the phase 3 STARTER-NET trial evaluating the combination of everolimus with lanreotide when used for the first-line treatment of patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors.

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, according to real-world data.

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage II/III rectal cancer.

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS G12D pancreatic ductal adenocarcinoma based on preliminary findings.

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in patients with KRAS G12D pancreatic ductal adenocarcinoma treated with zoldonrasib.

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.

Adagrasib plus cetuximab sustained clinical efficacy in KRAS G12C–mutant unresectable or metastatic colorectal cancer with longer follow-up, according to the KRYSTAL-1 trial.